BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis
暂无分享,去创建一个
Isabelle Tardy | Thierry Bettinger | Philippe Bussat | Sibylle Pochon | T. Bettinger | S. Pochon | Michel Schneider | P. Bussat | Michel Schneider | Jean Brochot | Lisa Passantino | Mathew von Wronski | I. Tardy | J. Brochot | L. Passantino | M. von Wronski
[1] Paul A Dayton,et al. Molecular ultrasound imaging using microbubble contrast agents. , 2007, Frontiers in bioscience : a journal and virtual library.
[2] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[3] M. Shibuya. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. , 2006, Journal of biochemistry and molecular biology.
[4] Andrej Lyshchik,et al. Relationship Between Retention of a Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)‐Targeted Ultrasonographic Contrast Agent and the Level of VEGFR2 Expression in an In Vivo Breast Cancer Model , 2008, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[5] S. Caruthers,et al. High Sensitivity: High-Resolution SPECT-CT/MR Molecular Imaging of Angiogenesis in the Vx2 Model , 2009, Investigative radiology.
[6] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[7] G. Gasparini,et al. Anti-VEGF therapy: the search for clinical biomarkers , 2008, Expert review of molecular diagnostics.
[8] Sanjiv S Gambhir,et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. , 2008, Radiology.
[9] M. Cremonesi,et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. , 1998, British Journal of Cancer.
[10] Peter Carmeliet,et al. Angiogenesis in life, disease and medicine , 2005, Nature.
[11] John C. Gore,et al. A Molecular Imaging Paradigm to Rapidly Profile Response to Angiogenesis-directed Therapy in Small Animals , 2009, Molecular Imaging and Biology.
[12] M. Backer,et al. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. , 2001, Bioconjugate chemistry.
[13] William R. Wagner,et al. Modulating Targeted Adhesion of an Ultrasound Contrast Agent to Dysfunctional Endothelium , 2002, Annals of Biomedical Engineering.
[14] W. Schmiegel,et al. Drug Insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies , 2008, Nature Clinical Practice Gastroenterology &Hepatology.
[15] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Stuart Foster,et al. Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis , 2007, Molecular imaging.
[17] John C Gore,et al. Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 Expression Using Targeted Contrast‐Enhanced High‐Frequency Ultrasonography , 2007, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[18] S. Delorme,et al. Pharmacodynamics of Streptavidin-Coated Cyanoacrylate Microbubbles Designed for Molecular Ultrasound Imaging , 2008, Investigative radiology.
[19] A. Popel,et al. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. , 2004, American journal of physiology. Heart and circulatory physiology.
[20] Wolfhard Semmler,et al. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects , 2008, Molecular Cancer Therapeutics.
[21] S. Pochon,et al. In vivo ultrasound imaging of thrombi using a target-specific contrast agent. , 2002, Academic radiology.
[22] Michael Reinhardt,et al. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. , 2004, Radiology.
[23] E. Marinelli,et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. , 2005, Protein engineering, design & selection : PEDS.
[24] Sanjiv S Gambhir,et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. , 2008, Radiology.
[25] R. Shohet,et al. Targeting vascular endothelium with avidin microbubbles. , 2005, Ultrasound in medicine & biology.
[26] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[27] Rolf A. Brekken,et al. Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature , 2007, Clinical Cancer Research.
[28] E. Marinelli,et al. A flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups. , 2006, Biopolymers.
[29] B. Yeh,et al. In Vivo Monitoring of Angiogenesis Inhibitory Treatment Effects by Dynamic Contrast-Enhanced Computed Tomography in a Xenograft Tumor Model , 2009, Investigative radiology.